403 related articles for article (PubMed ID: 33604289)
1. Comprehensive Analysis of Prognostic and Immune Infiltrates for E2F Transcription Factors in Human Pancreatic Adenocarcinoma.
Liu XS; Gao Y; Liu C; Chen XQ; Zhou LM; Yang JW; Kui XY; Pei ZJ
Front Oncol; 2020; 10():606735. PubMed ID: 33604289
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of E2F Transcription Factor Expression in Pancreatic Adenocarcinoma.
Luo L; Zhang G; Wu T; Wu G
Med Sci Monit; 2021 Nov; 27():e933443. PubMed ID: 34799547
[TBL] [Abstract][Full Text] [Related]
3. Expression, Prognosis, and Immune Infiltrates Analyses of E2Fs in Human Brain and CNS Cancer.
Liao P; Han S; Qu H
Biomed Res Int; 2020; 2020():6281635. PubMed ID: 33381564
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Clear Cell Renal Cell Carcinoma.
Zhang C; Cui Y; Wang G; Zhao W; Zhao H; Huang X; Zhang M; Li W
J Healthc Eng; 2021; 2021():5790416. PubMed ID: 34531966
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and immune infiltrates for the Chromobox (CBX) protein family in human pancreatic adenocarcinoma.
Li Q; Fu L; Wu D; Wang J
J Gastrointest Oncol; 2021 Oct; 12(5):2310-2324. PubMed ID: 34790394
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Values of E2F1/2 Transcriptional Expressions in Chromophobe Renal Cell Carcinoma Patients: Evidence from Bioinformatics Analysis.
Hu D; Meng N; Lou X; Li Z; Teng Y; Tu B; Zou Y; Wang F
Int J Gen Med; 2021; 14():3593-3609. PubMed ID: 34295182
[TBL] [Abstract][Full Text] [Related]
7.
Zhou Q; Zhang F; He Z; Zuo MZ
Front Oncol; 2019; 9():161. PubMed ID: 30967995
[No Abstract] [Full Text] [Related]
8. Comprehensive review regarding the association of E2Fs with the prognosis and immune infiltrates in human head and neck squamous cell carcinoma.
Du W; Xia X; Gou Q; Xie Y; Gao L
Asian J Surg; 2024 May; 47(5):2106-2121. PubMed ID: 38320907
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of E2F Family Members in Human Gastric Cancer.
Li S; Yang X; Li W; Chen Z
Front Oncol; 2021; 11():625257. PubMed ID: 34532281
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatics analysis identified MMP14 and COL12A1 as immune-related biomarkers associated with pancreatic adenocarcinoma prognosis.
Li Y; Su Z; Wei B; Qin M; Liang Z
Math Biosci Eng; 2021 Jun; 18(5):5921-5942. PubMed ID: 34517516
[TBL] [Abstract][Full Text] [Related]
11. Overexpressing PLOD Family Genes Predict Poor Prognosis in Pancreatic Cancer.
Zhang J; Tian Y; Mo S; Fu X
Int J Gen Med; 2022; 15():3077-3096. PubMed ID: 35330878
[TBL] [Abstract][Full Text] [Related]
12. Systematic Analysis of E2F Expression and Its Relation in Colorectal Cancer Prognosis.
Xu Z; Qu H; Ren Y; Gong Z; Ri HJ; Zhang F; Shao S; Chen X; Chen X
Int J Gen Med; 2022; 15():4849-4870. PubMed ID: 35585998
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Values and Clinical Significance of S100 Family Member's Individualized mRNA Expression in Pancreatic Adenocarcinoma.
Li X; Qiu N; Li Q
Front Genet; 2021; 12():758725. PubMed ID: 34804125
[No Abstract] [Full Text] [Related]
14. Novel Potential Therapeutic Target for E2F1 and Prognostic Factors of E2F1/2/3/5/7/8 in Human Gastric Cancer.
Liu X; Hu C
Mol Ther Methods Clin Dev; 2020 Sep; 18():824-838. PubMed ID: 32953933
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of the E2F Transcription Factor Family in Human Lung Adenocarcinoma.
Wang Q; Liu J; Cheang I; Li J; Chen T; Li Y; Yu B
Int J Gen Med; 2022; 15():5973-5984. PubMed ID: 35811776
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Biomarkers and Immunotherapeutic Targets Among CXC Chemokines in Pancreatic Adenocarcinoma.
Huang J; Chen Z; Ding C; Lin S; Wan D; Ren K
Front Oncol; 2021; 11():711402. PubMed ID: 34497764
[TBL] [Abstract][Full Text] [Related]
17. E2F1/2/4 mRNA is associated with immune infiltration and are potential biomarkers for the prognosis of human gastric carcinoma.
Chen Y; Gong W; Dai W; Jiang H; Xu X
Transl Cancer Res; 2021 Jun; 10(6):2801-2811. PubMed ID: 35116590
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
19. E2F1/2/7/8 as independent indicators of survival in patients with cervical squamous cell carcinoma.
Yang C; Zhang ZC; Liu TB; Xu Y; Xia BR; Lou G
Cancer Cell Int; 2020; 20():500. PubMed ID: 33061852
[TBL] [Abstract][Full Text] [Related]
20. A Potential Prognostic Marker PRDM1 in Pancreatic Adenocarcinoma.
Zhou B; Zhang J; Zhu H; Wu S
J Oncol; 2022; 2022():1934381. PubMed ID: 35607327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
